Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionHighTower Advisors, LLC
Latest Disclosed Ownership11,198 shares
Latest Disclosed Value $ 1,475,225
HighTower Advisors, LLC ownership in NBIX / Neurocrine Biosciences, Inc.

On May 5, 2026 - HighTower Advisors, LLC filed a 13F-HR form disclosing ownership of 11,198 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $1,475,225 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 12,271 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -8.74% during the quarter.

HighTower Advisors, LLC has a history of taking positions in derivatives of the underlying security (NBIX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:NBIX / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,198 -1,073 -8.74 1,475 -15.23 0.0016
2026-02-06 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,271 2,822 29.87 1,740 31.22 0.0019
2025-11-07 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,449 -214 -2.21 1,326 9.23 0.0015
2025-08-11 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,663 -21 -0.22 1,215 13.35 0.0015
2025-05-13 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,684 -916 -8.64 1,071 -25.93 0.0015
2025-02-07 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,600 1,013 10.57 1,447 30.98 0.0020
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,587 -19,785 -67.36 1,104 -72.90 0.0016
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,372 13,434 84.29 4,074 84.18 0.0063
2024-05-06 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,938 556 3.61 2,212 9.13 0.0036
2024-02-12 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,382 8,149 112.66 2,027 146.89 0.0034
2023-11-08 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,233 625 9.46 821 31.15 0.0015
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,608 -1,297 -16.41 626 -22.81 0.0012
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,905 -381 -4.60 811 -18.66 0.0018
2023-02-09 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,286 2,550 44.46 997 64.25 0.0023
2022-11-09 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,736 -57 -0.98 607 7.24 0.0016
2022-08-10 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,793 48 0.84 566 4.04 0.0015
2022-05-12 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,745 1,883 48.76 544 63.86 0.0012
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,862 -2,142 -35.68 332 -42.86 0.0007
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,004 -26,344 -81.44 581 -81.54 0.0016
2021-08-06 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 32,348 26,406 444.40 3,148 448.43 0.0091
2021-05-10 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,942 224 3.92 574 4.17 0.0018
2021-02-10 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,718 -2,465 -30.12 551 -30.16 0.0023
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,183 3,631 79.77 789 42.16 0.0038
2020-08-10 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,552 -131 -2.80 555 37.04 0.0030
2020-05-21 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,683 -267 -5.39 405 -23.87 0.0026
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,950 296 6.36 532 26.97 0.0031
2019-11-12 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,654 -34 -0.73 419 5.81 0.0023
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,688 226 5.06 396 0.76 0.0024
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,462 356 8.67 393 34.13 0.0026
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,106 -22 -0.53 293 -42.32 0.0022
2018-11-09 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,128 22 0.54 508 25.74 0.0037
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,106 -7 -0.17 404 18.13 0.0032
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,113 1,307 46.58 342 56.88 0.0029
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,806 2,806 218 0.0018
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM Call 300 2 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.